Joanna C Yang1, Stephanie A Terezakis2, Ira J Dunkel3,4, Stephen W Gilheeney3, Suzanne L Wolden1. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York. 2. Department of Radiation Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland. 3. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York. 4. Department of Pediatrics, Weill Cornell Medical College, New York.
Abstract
BACKGROUND: We sought to assess patterns of failure in pediatric patients with intracranial germ cell tumors (GCT) treated with intensity-modulated radiation therapy with dose painting (DP-IMRT). PROCEDURE: Between July 2007 and October 2013, 11 patients with localized GCT-five germinomas and six nongerminoma GCT (NGGCT)-received definitive treatment with DP-IMRT. Three representative patients were selected for replanning with (i) whole ventricular irradiation (WVI) with opposed lateral beams plus IMRT to the primary tumor and (ii) sequential IMRT. These plans were compared to the patients' original DP-IMRT plans for dosimetric analyses. RESULTS: Four patients with germinoma received radiation therapy alone: 45 Gy in 1.8 Gy fractions to the primary tumor and 25 Gy in 1.0 Gy fractions to whole ventricles using a dose-painting plan. One patient with germinoma received a reduced dose of 30.6 Gy to the primary tumor after neoadjuvant chemotherapy. Patients with NGGCT (n = 6) underwent multimodality treatment including chemotherapy (n = 6) and surgery (n = 3). These patients received 54 Gy to the primary tumor and 32.4-36 Gy to the whole ventricles. Dosimetric analyses showed DP-IMRT delivered decreased mean dose to whole brain, temporal lobes, hippocampi, cochleae, and optic nerves. With median follow-up of 4 years, 3-year failure-free survival was 100% for patients with germinoma and 67% for patients with NGGCT. One patient with a pineal NGGCT experienced a local recurrence within the high dose-volume while another experienced an isolated biochemical failure. CONCLUSIONS: DP-IMRT is dosimetrically superior to standard IMRT techniques for sparing of normal tissues. Disease control in this small series appears at least comparable to published results.
BACKGROUND: We sought to assess patterns of failure in pediatric patients with intracranial germ cell tumors (GCT) treated with intensity-modulated radiation therapy with dose painting (DP-IMRT). PROCEDURE: Between July 2007 and October 2013, 11 patients with localized GCT-five germinomas and six nongerminoma GCT (NGGCT)-received definitive treatment with DP-IMRT. Three representative patients were selected for replanning with (i) whole ventricular irradiation (WVI) with opposed lateral beams plus IMRT to the primary tumor and (ii) sequential IMRT. These plans were compared to the patients' original DP-IMRT plans for dosimetric analyses. RESULTS: Four patients with germinoma received radiation therapy alone: 45 Gy in 1.8 Gy fractions to the primary tumor and 25 Gy in 1.0 Gy fractions to whole ventricles using a dose-painting plan. One patient with germinoma received a reduced dose of 30.6 Gy to the primary tumor after neoadjuvant chemotherapy. Patients with NGGCT (n = 6) underwent multimodality treatment including chemotherapy (n = 6) and surgery (n = 3). These patients received 54 Gy to the primary tumor and 32.4-36 Gy to the whole ventricles. Dosimetric analyses showed DP-IMRT delivered decreased mean dose to whole brain, temporal lobes, hippocampi, cochleae, and optic nerves. With median follow-up of 4 years, 3-year failure-free survival was 100% for patients with germinoma and 67% for patients with NGGCT. One patient with a pineal NGGCT experienced a local recurrence within the high dose-volume while another experienced an isolated biochemical failure. CONCLUSIONS:DP-IMRT is dosimetrically superior to standard IMRT techniques for sparing of normal tissues. Disease control in this small series appears at least comparable to published results.
Authors: Thomas J Galloway; Daniel J Indelicato; Robert J Amdur; Erika L Swanson; Amy A Smith; Robert B Marcus Journal: Am J Clin Oncol Date: 2012-06 Impact factor: 2.339
Authors: S L Wolden; W M Wara; D A Larson; M D Prados; M S Edwards; P K Sneed Journal: Int J Radiat Oncol Biol Phys Date: 1995-07-15 Impact factor: 7.038
Authors: Brian De; Oren Cahlon; Ira J Dunkel; Kevin C De Braganca; Yasmin Khakoo; Stephen W Gilheeney; Mark M Souweidane; Suzanne L Wolden Journal: J Neurooncol Date: 2017-06-28 Impact factor: 4.130
Authors: Kenneth Wong; Anthony B Opimo; Arthur J Olch; Sean All; Jonathan F Waxer; Desirae Clark; Justine Cheng; Alisha Chlebik; Anat Erdreich-Epstein; Mark D Krieger; Benita Tamrazi; Girish Dhall; Jonathan L Finlay; Eric L Chang Journal: Cureus Date: 2016-04-25
Authors: Dora Correia; Dario Terribilini; Stefan Zepter; Alessia Pica; Nicola Bizzocchi; Werner Volken; Sonja Stieb; Frank Ahlhelm; Evelyn Herrmann; Michael K Fix; Peter Manser; Daniel M Aebersold; Damien C Weber Journal: Clin Transl Radiat Oncol Date: 2019-01-09
Authors: Ana Carolina Pires de Rezende; Eduardo Weltman; Michael Jenwei Chen; Juliana Karassawa Helito; Ícaro Thiago de Carvalho; Roberto Kenji Sakuraba; Nasjla Saba Silva; Andrea Maria Cappellano; Nelson Hamerschlak Journal: PLoS One Date: 2019-12-20 Impact factor: 3.240